Astrocytoma, IDH-Mutant, Grade 4 — Trials

Astrocytoma, IDH-Mutant, Grade 4 — Trials · CancerIndex

Clinical trials

Registered studies

16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 12
Recruiting: 9
Ph III recruiting: 1
Growth YoY: —
Industry share: 8%
Top sponsor: Mayo Clinic
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04145115	A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden	active not recruiting	Phase 2	37	National Cancer Institute (NCI)NIH	2	Aug 31, 2026	clinicaltrials
NCT05565521	UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly(UNITED2)	active not recruiting	Phase 2	55	Sunnybrook Health Sciences CentreOTHER	1